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Response to antiplatelet treatment: from genes to outcome
Dual antiplatelet therapy (aspirin plus clopidogrel) 
is the standard of care for patients with acute 
coronary syndrome who are managed medically or by 
percutaneous coronary intervention (PCI).1,2 Clopidogrel 
has substantial benefi t in patients undergoing PCI 
and stent implantation.1,2 However, major adverse 
cardiovascular events, including stent thrombosis, can 
occur despite antiplatelet therapy, and a recent meta-
analysis showed that persistent platelet reactivity on 
clopidogrel treatment confers a fi ve-fold increased risk 
of major adverse cardiovascular events.3
Multiple chronic or transient mechanisms involved 
in high on-clopidogrel platelet reactivity have been 
identifi ed: inadequate drug compliance, drug–drug 
interactions, age, diabetes, body-mass index, left-
ventricle ejection function, and infl ammation.4 Platelet 
response to clopidogrel is highly heritable and not 
entirely explained by CYP2C19, an isoform of the 
cytochrome P450 involved in clopidogrel’s metabolism, 
which suggests that further genetic variants in diff erent 
genes play a pivotal role in determining individual 
susceptibility to antiplatelet drug response.4,5 In 2007, the 
CYP2C19*2 polymorphism was found to be associated 
with residual platelet reactivity in patients with acute 
coronary syndrome who were undergoing PCI on 
antiplatelet treatment.6 Successively, in diff erent clinical 
settings and at diff erent follow-up, CYP2C19*2 and other 
allelic variants in this gene were shown to be independent 
determinants of major adverse cardiovascular events in 
patients on clopidogrel.4,7,8 In May, 2009, the US Food 
and Drug Administration recommended the change to 
clopidogrel’s prescribing label to refl ect these fi ndings.9
New P2Y12-receptor antagonists are now available. 
Prasugrel is a third-generation thienopyridine associated 
with greater active metabolite generation, superior 
inhibition of ADP-induced platelet aggregation, and 
less response variability than with clopidogrel.10 In the 
TRITON-TIMI 38 trial of patients with acute coronary 
syndrome who were undergoing PCI, the prevalence 
of cardiovascular death, non-fatal myocardial infarc-
tion, or stroke was lower with prasugrel than with 
clopidogrel.11 However, rates of bleeding were higher in 
the prasugrel group.
The novel antiplatelet agent ticagrelor was also 
evaluated against clopidogrel in patients with acute 
coronary syndrome in the PLATO trial.12 Ticagrelor was 
associated with signifi cant reduction in cardiovascular 
death, myocardial infarction, and stroke, without any 
diff erence in the overall incidence of major bleeding, 
but with an increase in major bleeding related to non-
coronary-artery bypass graft.
The issue of the optimum dose of clopidogrel and/or 
the personalisation of alternative antiplatelet therapeutic 
strategies aimed at reducing ischaemic events and 
minimisation of bleedings is open. We think that the 
relevance of obtaining an “adequate residual platelet 
reactivity” on antiplatelet treatment is now well founded 
and the crucial goal is now to identify the clinical, 
environmental, procedural, and genetic determinants of 
the increased risk of major adverse cardiovascular events 
and of bleedings in these high-risk patients.
In The Lancet today, Jessica Mega13 and Lars Wallentin,14 
and their respective colleagues, have addressed the 
important issue of fi nding further genetic variants 
beside those in CYP2C19 and beside the other clinical 
and procedural risk factors associated with major adverse 
cardiovascular events in patients with acute coronary 
syndrome who are on antiplatelet therapy. Both papers 
confi rmed the independent role of the CYP2C19 loss-
of-function alleles as a determinant of major adverse 
cardiovascular events in these patients on clopidogrel, 
even if with a lower impact in PLATO than in TRITON-
TIMI-38 or in the recent meta-analyses,7,8 whereas they 
did not show any eff ects of CYP2C19 genetic variants in 
patients on prasugrel13 or ticagrelor.14
The most interesting novel data from these two 
papers12,13 are those about the role of the 3435C→T 
polymorphism in ABCB1, a gene coding the 
P-glycoprotein involved in drug absorption, on the 
effi  cacy of the three diff erent antiplatelet treatments. 
Previous data, from patients presenting with an acute 
myocardial infarction in a nationwide French registry 
and receiving clopidogrel, showed that patients with 
two ABCB1 variant alleles (3435 TT genotype) had 
a higher rate of cardiovascular events at 1 year than 
did those with the 3435 CC genotype.15 However, 
in that study, the ABCB1 polymorphism was not an 
independent predictor of outcome in the subgroup 
of patients undergoing percutaneous coronary 
intervention.14 For the ABCB1 polymorphism, even 
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though both studies investigated relatively large 
populations, Mega and colleagues and Wallentin and 
colleagues obtained contrasting results. Mega and 
colleagues found that patients on clopidogrel who 
had the ABCB1 3435 TT genotype were at increased 
risk of recurrent ischaemic events, probably due to 
less platelet inhibition according to their observations 
in healthy individuals. On the other hand, Wallentin 
and colleagues observed a numerically higher rate of 
primary effi  cacy events for the high-expression group 
(patients with the ABCB1 3435 CC genotype) who were 
on clopidogrel.
Interpreting the results from the two studies, we 
should consider that several important diff erences 
occur or are not deeply valuable—eg, clinical setting 
(in the PLATO cohort, only two-thirds of patients were 
managed invasively), severity of disease, available 
clinical information, geographic origin, and percentage 
of platelets naive to antiplatelet treatment. On the other 
hand, few and contrasting data are available on the 
possible eff ect of the 3435C→T ABCB1 polymorphism 
on clopidogrel’s absorption or metabolism.16–18
The fact that prasugrel’s and ticagrelor’s effi  cacy was 
not infl uenced by CYP2C19 and ABCB1 polymorphisms 
does not mean that other polymorphisms in diff erent 
genes (eg, CYP3A4 or CYP3A5) could not aff ect their 
pharmacodynamics and pharmacokinetics. In fact, on 
the basis of available knowledge, CYP2C19 and ABCB1 
have a marginal or no role on prasugrel’s and ticagrelor’s 
metabolism and absorption.
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Figure: Mechanism of action and metabolic pathways for clopidogrel, prasugrel, and ticagrelor
All three drugs are absorbed intestinally. In this step, P-glycoprotein, encoded ABCB1, could intervene. Clopidogrel is mostly hydrolysed by esterases to inactive carboxylic acid derivative that accounts for 
85% of clopidogrel-related circulating compounds. Several cytochrome P450 (CYP450) enzyme isoforms are responsible for oxidation of thiophene ring of clopidogrel to 2-oxo-clopidogrel, which is further 
oxidised by other CYP450 isoforms to result in opening of the thiophene ring and formation of carboxyl and thiol groups. Thiol group irreversibly binds to ADP P2Y12 receptor expressed on platelet surface 
and causes irreversible blockade of ADP binding. Prasugrel is rapidly hydrolysed by carboxyesterases to a thiolactone (R-95913), which is subsequently metabolised to the prasugrel-active metabolite, 
R-138727. Conversion of R-95913 to R-138727 is catalysed by several CYP450 enzymes, with greatest contributions from CYP3A and CYP2B6, lesser contributions from CYP2C9 and CYP2C19, and even less 
from CYP2D6. Active metabolite of prasugrel irreversibly binds to ADP P2Y12 receptor. Unlike the other two thienopyridines, ticagrelor does not need to be converted by liver into active metabolite, and is a 
reversible ADP-receptor antagonist. P-gp=P-glycoprotein. ABCB1=ATP-binding cassette sub-family B member 1. Dotted arrow=no liver conversion and reversible binding to P2Y12 receptor.
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The temptation to fi nd the easier way by choosing 
the “superior” drug on the basis of large trials in which 
participants with diff erent risk profi les venture to be 
considered equal is not desirable. The issue is not to 
choose the lesser of the evils, but the better of the 
goods—by identifying the therapeutic strategy that, 
in consideration of individual characteristics, warrants 
the higher benefi t/risk ratio. Evaluation of the best 
management should also take into account the clinical 
determinants of platelet reactivity—from age and sex to 
body-mass index, diabetes, and infl ammation—which 
might modulate platelet function, while also considering 
the timing from the acute event, as shown by the 
CURRENT-OASIS 7 study.19
For this purpose, starting from these experiences, the 
scientifi c community should draw the indications to 
standardise experimental designs. Prospective studies 
evaluating diff erent antiplatelet treatments tailored to 
individual characteristics of patients—genetic profi le, 
residual platelet reactivity, drug–drug interactions, and 
traditional and procedural risk factors—are urgently 
needed to identify therapeutic strategies that will 
provide the best benefi t for the single patient in this 
high-risk clinical setting.
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